<DOC>
	<DOC>NCT01542736</DOC>
	<brief_summary>To study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.</brief_summary>
	<brief_title>Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)</brief_title>
	<detailed_description />
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age greater than 3 years and less than 25 years Patients with classic histology or desmoplastic histology metastatic medulloblastoma by histological diagnosis and by head and spine MRI. Patients with anaplastic histology will be excluded. Patients with highrisk supratentorial, nonmetastatic, PNET Patients with metastatic PNET Newly diagnosed patients who have not received prior therapy, with the exception of one short course of emergent chemotherapy in newly presenting patients with neurological compromise per provider decision Only patients who are expected to survive at least 6 weeks will be eligible for this study. Patients who are pregnant may not be treated on this study</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>